Find disease awareness content and relevant supporting materials

Areas covered: This article reviews the clinical efficacy and safety of oral and intravenous lasmiditan as a possible acute migraine treatment. We analyze all currently available results in Phase I to III studies.

Eli Lilly and Company has announced the submission of a New Drug Application (NDA) to the FDA for lasmiditan for...

Eli Lilly and Company and CoLucid Pharmaceuticals announced an agreement for Lilly to acquire CoLucid for $46.50 per share or...

The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Eli Lilly and Company announced that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its...

Migraine is a common and highly disabling neurological disorder associated with a high socioeconomic burden. Effective migraine management depends on adequate patient education: to avoid unrealistic expectations, the condition must be...

CoLucid Pharmaceuticals provided additional data regarding onset of action demonstrated as soon as 30 minutes after dosing for 100 mg...

Eli Lilly and Company presented key primary and secondary endpoint data at the 18th Congress of the International Headache Society...

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Eli Lilly announced new data and post-hoc analyses for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of...